Reply to Letter to the Editor: Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”

Documenti analoghi

• Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”
  di: Wei Huang, et al.
  Pubblicazione: (2024)
• Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapy
  di: Yusuke Kawamura, et al.
  Pubblicazione: (2024)
• Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma
  di: Teh‐Ia Huo, et al.
  Pubblicazione: (2024)
• Deciphering the dual nature of the Fibrosis‐4 index in predicting hepatocellular carcinoma risk among hepatitis B patients undergoing nucleos(t)ide analog therapy
  di: Jun Arai, et al.
  Pubblicazione: (2024)
• Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real‐world study
  di: Jun‐Zhe Yi, et al.
  Pubblicazione: (2024)